But -- and this is a critical point -- it can and will continue to make billions from sales of Wegovy even if Zepbound is better in most respects. The reason for this is simple: Eli Lilly can barely ...

ES Foundry, a US-owned solar cell producer, has secured its first gigawatt-plus, multi-year contract with a top-tier solar module manufacturer. The cell manufacturer started production this month ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse ...

Medications such as Zepbound, surgery, and CPAP treatment are all options. Lifestyle changes, such as losing weight, can improve sleep apnea symptoms. Contact your healthcare provider about symptoms ...

Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...

Lilly’s total revenues for the fourth quarter fell short of expectations due to lower-than-expected sales of its popular GLP-1 drugs, Mounjaro for type II diabetes and Zepbound for obesity.

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...

Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...